EMEA-000689-PIP01-09-M11
Key facts
| Invented name |
|
| Active substance |
exenatide
|
| Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
| Decision number |
P/0064/2021
|
| PIP number |
EMEA-000689-PIP01-09-M11
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com
Tel: +46 855327591 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000689-PIP01-09-M11
|
| Compliance opinion date |
21/05/2021
|
| Compliance outcome |
positive
|